[ad_1]
Dr. Lily Weckx, facing the first trials announced in the country to develop the Oxford immunizer, in partnership with the pharmaceutical laboratory AstraZeneca, reinforces the importance of making other vaccines available to immunize the population in the fight against covid-19. “Brazil needs all the vaccines,” he said, in an interview with Veja magazine.
With 686 deaths in the last 24 hours, Brazil already has more than 181 deaths from the disease caused by the new coronavirus.
One of the main bets of the federal government for the development of a vaccination program starting in 2021, the study has already had the participation of more than 10,000 volunteers.
Coordinator of the Special Immunobiological Reference Center of the Federal University of São Paulo (Unifesp), Lily Weckx it still projects an efficacy of more than 90% in these types of drugs, despite a range that ranged from 62% to 90% of effectiveness in the UK tests. “There is still more than half the way to go, but we are on the right track,” he analyzed.
According to the specialist, no further tests are needed to certify the validity of the product with Anvisa (National Health Surveillance Agency). “It is a vaccine that has full capacity to request registration, since it exceeds the minimum 50% effectiveness required,” he said. in an interview with Veja.
It also reinforced the positive impact of the immunizer in preventing the worsening of symptoms caused by the virus. And it guaranteed that it poses no risks to patients.
“The vaccine has great potential to prevent severe developments of covid-19. It is an immunizing agent that does not present any risk to the recipient. We are facing an effective, easy-to-use immunizer that can have a significant impact on reducing the pandemic. We will have a vaccine that makes a difference ”, he argued.
